Merck stock price forecast: bullish bias and tight range as MRK holds near highs

Merck stock price forecast: bullish bias and tight range as MRK holds near highs
Merck drops 1.04% to $121.41 today

Merck announced that the FDA has granted Priority Review for a new treatment option for certain patients with extensive-stage small cell lung cancer.

Merck is collaborating with Daiichi Sankyo on this development. The company shared a link for further information.

Highlights

  • MRK maintains a robust uptrend across short, medium, and long-term timeframes, staying above major support levels.
  • Momentum and trend indicators suggest strong bullish sentiment, though some oscillators indicate possible short-term consolidation or pullback.
  • MRK is likely to consolidate within the $119.22 to $124.00 range, with an 80% probability of further upside and limited downside risk.

Multi-timeframe bullish structure as price holds key moving averages

MRK is trading above the MA-20 ($118.35), MA-50 ($118.60), and well above the MA-200 ($97.43), confirming a strong upward structure for both the short, medium, and long term. The Ichimoku Kijun at $118.37 sits below the current price, acting as immediate support. Near-term support is at the cluster of MA-20 and Ichimoku Kijun around $118.35–$118.37, while the key support lies at the MA-50 ($118.60). Resistance is found near MA-5 ($121.48) and MA-10 ($120.71), with the key resistance at $122.49 marked by the HMA.

Bullish momentum prevails despite oscillator divergence and overbought signals

Momentum signals are moderately bullish on D1, with MACD indicating a buy and ADX remaining neutral. RSI and CCI are in buy territory, while Stoch RSI flashes a strong sell, resulting in some divergence among oscillators. BBP is overbought at 2.74, highlighting buyer dominance in the broader trend, yet intraday signals and some oscillators warn of possible short-term corrective pressure. AO supports the bullish trend, aligning with higher timeframe buys. MRK is trading at $121.41, up from a previous week close of $120.78—a 0.52% gain. The stock is positioned in the upper part of its weekly range, with weekly volatility at 6.44%. Price action this week shows consolidation near the highs after recovering sharply from the weekly low of $116.50. In today’s session, the stock slipped 1.04%, suggesting minor pullback after testing resistance.

Upside favored as strong trend limits near-term downside risk

Looking to the coming week, the expected price range for MRK is $119.22 to $124.00, keeping the stock well above its 52-week low of $73.31 and approaching the 52-week high of $125.14. The probability of further price increase is very high (more than 80%) based on bullish signals from RSI-W1, ADX-W1, MACD-W1, and MA-50-W1. The likelihood of a move lower is accordingly very low. Baseline scenario is sideways consolidation between $119.22 and $124.00. In a bullish scenario, a break above $124.00 opens the path toward a retest of the yearly high. On the downside, a dip below $119.22 would target the next cluster of support in the $118.35–$118.60 area, but the prevailing trend suggests downside risk is limited for now.

Previously, analysts noted that Merck was facing ongoing bearish momentum despite short-term gains, with caution advised amid weak underlying indicators. In light of the latest developments, traders should closely monitor for a sustained shift in trend direction, as confirmation of either renewed downside risk or a potential reversal remains key for the sessions ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.